Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs

BioNanoScience

Volumn 2, Issue 4, 2012, Pages 227-250

  Kumar, Sandeep ^a   Dilbaghi, Neeraj ^a   Saharan, Ruma ^a   Bhanjana, Gaurav ^a  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Cellular uptake and cytotoxicity; Drug loading and release; Lipid based nanoparticles; Lipid polymer hybrid nanoparticles; Polymer based nanoparticles; Zeta potential

Indexed keywords

CELLULAR UPTAKE; DELIVERY VEHICLE; DRUG LOADING; HYBRID NANOPARTICLE; IMAGING AGENT; NANOPARTICLE FORMULATION; NANOPARTICULATE DRUG DELIVERY SYSTEMS; POORLY WATER-SOLUBLE DRUGS; THERAPEUTIC APPLICATION;

FUNCTIONAL POLYMERS; LOADING; MEDICAL APPLICATIONS; NANOTECHNOLOGY; VEHICLES; ZETA POTENTIAL;

NANOPARTICLES;

CARBOXYMETHYLCELLULOSE; CHITOSAN; CHONDROITIN SULFATE; CYANOCOBALAMIN; DEXAMETHASONE; DEXTRAN SULFATE; DNA; DOCETAXEL; DOXORUBICIN; ETHAMBUTOL; FLUOROURACIL; FOLIC ACID; HEMATOPORPHYRIN; HEPARIN; HYALURONIC ACID; ISONIAZID; NANOCARRIER; PACLITAXEL; POLYELECTROLYTE; POLYMER; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; TRIPOLYPHOSPHATE;

BLOOD BRAIN BARRIER; COACERVATION; CONJUGATE; COVALENT BOND; CYTOTOXICITY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; EVAPORATION; GELATION; GENE TARGETING; HUMAN; KUPFFER CELL; METABOLISM; MICROEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 84868697294     PISSN: 21911630     EISSN: 21911649     Source Type: Journal    
DOI: 10.1007/s12668-012-0060-7     Document Type: Review

References (222)

1. Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25.
2. Klopman, G., & Zhu, H. (2001). Estimation of aqueous solubility of organic molecules by the group contribution approach. Journal of Chemical Information and Computer Sciences, 41(2), 439-445. doi: 10. 1021/ci000152d.
3. Brigger, I., Dubernet, C., Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 54(5), 631-651. doi: 10. 1016/S0169-409X(02)00044-3.
4. Amidon, G. L., Lennernas, H., Shah, V. P., Crison, J. R. A. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413-419. doi: 10. 1023/A: 1016212804288.
5. Yu, L. X., Amidon, G. L., et al. (2002). A biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 19(7), 921-925. doi: 10. 1023/A: 101647360163.
6. Gothoskar, A. V. (2005). Biopharmaceutical classification of drugs. Pharmacy Review. Available from: http://www. pharmainfo. net/reviews/biopharmaceutical-classification-drugs. Accessed: 18 Jun 2012.
7. Thiel-Demby, V. E., Humphreys, J. E., et al. (2009). Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Molecular Pharmaceutics, 6(1), 11-18. doi: 10. 1021/mp800122b.
8. Chen, M., Amidon, G. L., Benet, L. Z., Lennernas, H., Yu, L. X. (2011). The BCS, BDDCS, and regulatory guidances. Pharmaceutical Research, 28(7), 1774-1778. doi: 10. 1007/s11095-011-0438-1.
9. Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. European Journal of Pharmaceutical Sciences, 29(3-4), 278-287. doi: 10. 1016/j. ejps. 2006. 04. 016.
10. Urbanetz, N. A. (2006). Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. The European Journal of Pharmaceutical Sciences, 28(1-2), 67-76. doi: 10. 1016/j. ejps. 2005. 12. 009.
11. Noyes, A. A., & Whitney, W. R. (1897). The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society, 19, 930-934. doi: 10. 1021/ja02086a003.
12. Liversidge, G., & Cundy, K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. International Journal of Pharmaceutics, 125, 91-97. doi: 10. 1016/0378-5173(95)00122-Y.
13. Benet, L. Z. (2008). Bioavailability and bioequivalence: focus on physiological factors and variability. Pharmaceutical Research, 25(8), 1956-1962. doi: 10. 1007/s11095-008-9645-9.
14. Tom, J. W., & Debenedetti, P. G. (1991). Particle formation with supercritical fluids-a review. Journal of Aerosol Science, 22(5), 555-584. doi: 10. 1016/0021-8502(91)90013-8.
15. Horn, D., & Rieger, J. (2001). Organic nanoparticles in the aqueous phase theory, experiment, and use. Angewandte Chemie (International Ed. in English), 40(23), 4330-4361. doi: 10. 1002/1521-3773(20011203)40: 23< 4330:: AID-ANIE4330> 3. 0. CO; 2-W.
16. Muller, R. H., Jacobs, C., Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect in the future. Advanced Drug Delivery Reviews, 47(1), 3-19. doi: 10. 1016/S0169-409X(00)00118-6.
17. Rabinow, B. E. (2004). Nanosuspensions in drug delivery. Nature Reviews Drug Discovery, 3(9), 785-796. doi: 10. 1038/nrd1494.
18. Merisko-Liversidge, E., Liversidge, G. G., Cooper, E. R. (2004). Nanosizing: a formulation approach for poorly water-soluble compounds. European Journal of Pharmaceutical Sciences, 18(2), 113-120. doi: 10. 1016/S0928-0987(02)00251-8.
19. Suzuki, H., Ogawa, M., Hironaka, K., Ito, K., Sunada, H. (2001). A nifedipine coground mixture with sodium deoxycholate. II. Dissolution characteristics and stability. Drug Development International Pharmacy, 27(9), 951-958. doi: 10. 1081/DDC-100107676.
20. List, M., Sucker, H. (1998). Pharmaceutical colloidal hydrosols for injection. GB patent no. 2200048.
21. Rogers, T. L., et al. (2002). A novel particle engineering technology: spray-freezing into liquid. International Journal of Pharmaceutics, 242(1-2), 93-100. doi: 10. 1016/S0378-5173(02)00154-0.
22. Hua, J., Keith, P., Johnston, B., Robert, O., Williams, A. (2004). Rapid dissolving high potency danazol powders produced by spray freezing into liquid process. International Journal of Pharmaceutics, 271, 145-154. doi: 10. 1016/j. ijpharm. 2003. 11. 003.
23. Ribeiro, D. S., Richard, J. B. P., Thiesc, C., Benoit, J. P. (2002). Microencapsulation of protein particles within lipids using a novel supercritical fluid process. International Journal of Pharmaceutics, 242(1), 69-78. doi: 10. 1016/S0378-5173(02)00149-7.
24. Pathak, P., Meziani, M. J., Sun, Y.-P. (2005). Supercritical fluid technology for enhanced drug delivery. Expert Opinion on Drug Delivery, 2(4), 747-761. doi: 10. 1517/17425247. 2. 4. 747.
25. Waard, H. D., Hinrichs, W. L. J., Frijlink, H. W. (2008). A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. Journal of Controlled Release, 128(2), 179-183. doi: 10. 1016/j. jconrel. 2008. 03. 002.
26. Pouton, C. W. (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and "self-microemulsifying" drug delivery systems. European Journal of Pharmaceutical Sciences, 11, 93-98. doi: 10. 1016/S0928-0987(00)00167-6.
27. Kawakami, K., Yoshikawa, T., Mororo, Y., Hayashi, T. (2002). Microemulsion formulation for enhanced absorption of poorly soluble drugs: I prescription design. Journal of Controlled Release, 81(1-2), 65-74. doi: 10. 1016/S0168-3659(02)00049-4.
28. Letchford, K., & Burt, H. (2007). A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymerosomes. European Journal of Pharmaceutics and Biopharmaceutics, 65, 259-269. doi: 10. 1016/j. ejpb. 2006. 11. 009.
29. GuFX, K. R., WangAZ, A. F. E., et al. (2007). Targeted nanoparticles for cancer treatment. Nano Today, 2, 14-21. doi: 10. 1016/S1748-0132(07)70083-X.
30. Tong, R., & Cheng, J. J. (2007). Anticancer polymeric nanomedicines. Polymer Reviews, 47, 345-381. doi: 10. 1080/15583720701455079.
31. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews. Drug Discovery, 4(2), 145-160. doi: 10. 1038/nrd1632.
32. Torchilin, V. P. (2007). Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical Research, 24(1), 1-16. doi: 10. 1007/s11095-006-9132-0.
33. Merisko-Liversidge, E. M., & Liversidge, G. G. (2008). Drug nanoparticles: formulating poorly water-soluble compounds. Toxicologic Pathology, 36(1), 43-48. doi: 10. 1177/0192623307310946.
34. Hu, J., Johnston, K. P., Williams, R. O. (2004). Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Development and Industrial Pharmacy, 30(3), 233-245. doi: 10. 1081/DDC-120030422.
35. Jani, P. U., Florence, A. T., McCarthy, D. E. (1992). Further histologicalevidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. International Journal of Pharmaceutics, 84, 245-252. doi: 10. 1016/0378-5173(92)90162-U.
36. Hillery, A. M., & Florence, A. T. (1996). The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60 nm polystyrene particles after oral administration in the rat. International Journal of Pharmaceutics, 132, 123-130. doi: 10. 1016/0378-5173(95)04353-5.
37. Rajput, G., Majmudar, F., Patel, J., Thakor, R., Rajqor, N. B. (2010). Stomach-specific mucoadhesive microsphere as a controlled drug delivery system. Systemic Reviews in Pharmacy, 1(1), 70-78. doi: 10. 4103/0975-8453. 59515.
38. Peters, K., & Muller, R. H. (1998). Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. International Journal of Pharmaceutics, 160(2), 229-237. doi: 10. 1016/S0378-5173(97)00311-6.
39. Langguth, P., Hanafy, A., Frenzel, D., Grenier, P., et al. (2005). Nanosuspension formulationsfor low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Development & Industry Pharmacy, 31(3), 319-321. doi: 10. 1081/DDC-52182.
40. Kocbek, P., Baumgartner, S., Kristl, J. (2006). Preparation and evaluationof nanosuspensions for enhancing the dissolution of poorly water-soluble drugs. International Journal of Pharmaceutics, 312(1-2), 179-186. doi: 10. 1016/j. ijpharm. 2006. 01. 008.
41. Horter, D., & Dressman, J. B. (2001). Influence of physicochemical propertieson dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews, 46(1-3), 75-87. doi: 10. 1016/S0169-409X(00)00130-7.
42. Mamo, T., Moseman, E. A., Kolishetti, N., Salvador-Morales, C., et al. (2010). Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine, 5(2), 269-285. doi: 10. 2217/nnm. 10. 1.
43. Hanel, J. (2010). Biodegradable nanosized particles to deliver sustained-release medication cargo. Nanomedicine: nanomateral. PNAS, 2009(106), 19268-19273. Published online: Azonano. com; The A to Z of nanotechnology.
44. Soutter, W. (2012). Nanotechnology-based cancer treatment can reduce side effects. Nanomedicine: nanomateral. Published online. Available at: http://www. azonano. com/news. aspx?newsID=25010. Last accessed on 25 Jun 2012.
45. Zhang, L., & Zhang, L. G. (2010). Lipid-polymer hybrid nanoparticles: synthesis, characterization and application. Nano LIFE, 1(1-2), 163-173. doi: 10. 1142/S179398441000016X.
46. Mahapatro, A., & Singh, D. K. (2011). Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. Journal of Nanobiotechnology, 9, 55-67. doi: 10. 1186/1477-3155-9-55.
47. Jong, W. H. D., & Borm, P. J. A. (2008). Drug delivery and nanoparticles: applications and hazards. International Journal of Nanomedicine, 3(1), 133-149 PMCID: PMC2527668.
48. BormPJ, M.-S. D. (2006). Nanoparticles in drug delivery and environmental exposure: same size, same risk? Nanomedicine, 1(2), 235-249. doi: 10. 2217/17435889. 1. 2. 235.
49. Labhasetwar, V., Song, C., Levy, R. J. (1997). Nanoparticle drug delivery system forrestenosis. Advanced Drug Delivery Reviews, 24(1), 63-85. doi: 10. 1016/S0169-409X(96)00483-8.
50. Langer, R. (2000). Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Accounts of Chemical Research, 33(2), 94-101. doi: 10. 1021/ar9800993.
51. Bhadra, D., Bhadra, S., Jain, P., Jain, N. K. (2003). A PEGylated dendritic nanoparticulate carrier of fluorouracil. International Journal of Pharmaceutics, 257(1-2), 111-124. doi: 10. 1016/S0378-5173(03)00132-7.
52. Kommareddy, S., Tiwari, S. B., Amiji, M. M. (2005). Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technology in Cancer Research & Treatment, 4(6), 615-625.
53. Hans, M. L., & Lowman, A. M. (2002). Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science, 6(4), 319-327. doi: 10. 1016/S1359-0286(02)00117-1.
54. Sonia, T. A., & Sharma, C. P. (2011). Chitosan and its derivatives for drug delivery perspective. Advances in Polymer Science, 243, 23-54. doi: 10. 1007/12_2011_117.
55. Ubrich, N., Schmidt, C., Bodmeier, R., Hoffman, M., Maincent, P. (2005). Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. International Journal of Pharmaceutics, 288(1), 169-175. doi: 10. 1016/j. ijpharm. 2004. 09. 019.
56. Illum, L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Research, 15, 1326-1331. doi: 10. 1023/A: 1011929016601.
57. Kreuter, J. (1994). Nanoparticles. In J. Kreuter (Ed.), Colloidal drug delivery systems (pp. 261-276). New York: Marcel Dekker.
58. Muller, R. H. (1991). Colloidal carriers for controlled drug delivery and targeting, modification, characterization and in vivo distribution. Boston: CRC Press.
59. Agnihotri, S. A., Mallikarjuna, N. N., Aminabhavi, T. M. (2004). Recent advances on chitosan-based micro- and nanoparticles in drug delivery. Journal of Controlled Release, 100(1), 5-28. doi: 10. 1016/j. jconrel. 2004. 08. 010.
60. Prabaharan, M., & Mano, J. F. (2005). Chitosan-based particles as controlled drug delivery systems. Drug Delivery, 12(1), 41-57. doi: 10. 1080/10717540590889781.
61. Aspden, T. J., Mason, J. D., Jones, N. S. (1997). Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. Journal of Pharmaceutical Sciences, 86(4), 509-513. doi: 10. 1021/js960182o.
62. Mao, H. Q., Troung-le, V. L., Janes, K. A., Roy, K., Wang, Y., August, J. T., Leong, K. W. (2001). Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. Journal of Controlled Release, 70(3), 399-421. doi: 10. 1016/S0168-3659(00)00361-8.
63. Wang, X., Chi, N., Tang, X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. European Journal of Pharmaceutics and Biopharmaceutics, 70(3), 735-740. doi: 10. 1016/j. ejpb. 2008. 07. 005.
64. Calvo, et al. (1997). Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. Journal of Applied Polymer Science, 63, 125-132. doi: 0021-8995/97/010125-08.
65. Bodmeier, R., Chen, H. G., Paeratakul, O. (1989). A novel approach to the oral delivery of micro- or nanoparticles. Pharmaceutical Research, 6(5), 413-417. doi: 10. 1023/A: 1015987516796.
66. Pan, Y., Li, Y. J., Zhao, H. Y., Zheng, J. M., Xu, H., Wei, G., Hao, J. S., Cui, F. D. (2002). Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. International Journal of Pharmaceutics, 249(1-2), 139-147. doi: 10. 1016/S0378-5173(02)00486-6.
67. Dustgani, A., Fasahani, E. V., Imani, M. (2012). Preparation and in vitro characterization of chitosan nanoparticles containing Mesobuthus eupeus scorpion venom as an antigen delivery system. Journal of Venomous Animals and Toxins including Tropical Diseases, 18(1), 44-52. doi: 10. 1590/S1678-91992012000100006.
68. Shi, L. E., & Tang, Z. X. (2007). Adsorption of nuclease p1 on chitosan nano-particles. Brazilian Journal of Chemical Engineering, 26(2), 223-228. doi: 10. 1590/S0104-66322009000200022.
69. Gan, Q., Wang, T., Cochrane, C., McCarron, P. (2005). Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids and Surfaces B, 44(2-3), 65-73. doi: 10. 1016/j. colsurfb. 2005. 06. 001.
70. Tsai, M. L., Bai, S. W., Chen, R. H. (2008). Cavitation effects versus stretch effects resulted in different size and polydispersity of ionotropic gelation chitosan-sodium tripolyphosphate nanoparticle. Carbohydrate Polymers, 71(3), 448-457.
71. López-León, T., Carvalho, E. L., Seijo, B., Ortega-Vinuesa, J. L., Bastos-González, D. (2005). Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behavior. Journal of Colloid and Interface Science, 283(2), 344-351. doi: 10. 1016/j. jcis. 2004. 08. 186.
72. Sarmento, B., Ribeiro, A. J., Veiga, F., Ferreira, D. (2007). Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharmaceutical Research, 24(12), 2198-2206. doi: 10. 1007/s11095-007-9367-4.
73. Vila, A., Sánchez, A., Janes, K., Behrens, I., Kissel, T., Vila Jato, J. L., Alonso, M. J. (2004). Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. The European Journal of Pharmaceutical, 57(1), 123-131. doi: 10. 1016/j. ejpb. 2003. 09. 006.
74. Fernandez-Urrusuno, R., Calvo, P., Remunan-Lopez, C., Vila-Jato, J. L., Alonso, M. J. (1999). Enhancement of nasal absorbtion of insulin using chitosan nanoparticles. Pharmaceutical Research, 16, 1576-1581. doi: 10. 1023/A: 1018908705446.
75. Aktas, Y., Andrieux, K., Alonso, M. J., Calvo, P., Gürsoy, R. N., Couvreur, P., Capan, Y. (2005). Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. International Journal of Pharmaceutics, 298, 378-383. doi: 10. 1016/j. ijpharm. 2005. 03. 027.
76. DeCampos, A. M., & Alonso, M. J. (2001). Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface: application to cyclosporine A. International Journal of Pharmaceutics, 224(1-2), 116-159. doi: 10. 1016/S0378-5173(01)00760-8.
77. Shu, X. Z., & Zhu, K. J. (2000). A novel approach to prepare tripolyphosphate/chitosan complex beads for controlled release drug delivery. International Journal of Pharmaceutics, 201(1), 51-58. doi: 10. 1016/S0378-5173(00)00403-8.
78. Cetin, M., Atila, A., Kadioglu, Y. (2010). Formulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium. AAPS PharmSciTech, 11(3), 1250-1256. doi: 10. 1208/s12249-010-9489-6.
79. Avadi, M. R., Sadeghi, A. M. M., Mohammadpour, N., et al. (2010). Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomedicine: Nanotechnology, Biology and Medicine, 6(1), 58-63. doi: 10. 1016/j. nano. 2009. 04. 007.
80. Maitra, A. N., Ghosh, P. K., De, T. K., Sahoo, S. K. (1999) Process for the preparation of highly monodispersed hydrophilic polymeric nanoparticles of size less than 100 nm. US patent 5, 874, 111.
81. Ohya, Y., Shiratani, M., Kobayashi, H., Ouchi, T. (1993). Release behavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. Journal of Microencapsulation, 10(1), 1-9. doi: 10. 3109/02652049309015307.
82. Goldberg, M., Langer, R., Jia, X. (2007). Nanostructured materials for applications in drug delivery and tissue engineering. Journal of Biomaterials Science, Polymer Edition, 18(3), 241-268. doi: 10. 1163/156856207779996931.
83. Mitra, S., Gaur, U., Ghosh, P. C., Maitra, A. N. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. Journal of Controlled Release, 74(1-3), 317-323. doi: 10. 1016/S0168-3659(01)00342-X.
84. 4-chitosan nanoparticles used for hyperthermia. Advanced Powder Technology, 21(4), 461-467. doi: 10. 1016/j. apt. 2010. 01. 008.
85. Denuziere, A., Ferrier, D., Damour, O., Domard, A. (1998). Chitosan-chondroitin sulfate and chitosan-hyaluronate polyelectrolyte complexes: biological properties. Biomaterials, 19(14), 1275-1285. doi: 10. 1016/S0142-9612(98)00036-2.
86. Chen, Y., Mohanraj, V. J., Parkin, J. E. (2003). Chitosan-dextran sulfate nanoparticles for delivery of an anti-angiogenesis peptide. International Journal of Peptide Research and Therapeutics, 10(5-6), 621-629. doi: 10. 1007/s10989-004-2433-4.
87. Chen, Y., Mohanraj, V. J., Wang, F., Benson, H. A. E. (2007). Designing chitosan-dextran sulfate nanoparticles using charge ratios. AAPS PharmSciTech, 8(4), 131-139. doi: 10. 1208/pt0804098.
88. Ichikawa, S., Iwamoto, S., Watanabe, J. (2005). Formation of biocompatible nanoparticles by self-assembly of enzymatic hydrolysates of chitosan and carboxymethyl cellulose. Bioscience, Biotechnology, and Biochemistry, 69(9), 1637-1642. doi: 10. 1271/bbb. 69. 1637.
89. Liu, Z., Jiao, Y., Liu, F., Zhang, Z. (2007). Heparin/chitosan nanoparticle carriers prepared by polyelectrolyte complexation. Journal of Biomedical Materials Research Part A, 83(3), 806-812. doi: 10. 1002/jbm. a. 31407.
90. Tan, Q., Tang, H., Hu, J., Hu, Y., Zhou, X., Tao, Y., Wu, Z. (2011). Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds. International Journal of Nanomedicine, 6, 929-942. doi: 10. 2147/IJN. S18753.
91. Tiyaboonchai, W., & Limpeanchob, N. (2007). Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. International Journal of Pharmaceutics, 329(1-2), 142-149. doi: 10. 1016/j. ijpharm. 2006. 08. 013.
92. Erbacher, P., Zou, S., Bettinger, T., Steffan, A. M., Remy, J. S. (1998). Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharmaceutical Research, 15(9), 1332-1339. doi: 10. 1023/A: 1011981000671.
93. Sarmento, B., Martins, S., Ribeiro, A., Veiga, F., Neufeld, R., Ferreira, D. (2006). Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. The International Journal of Peptide Research and Therapeutics, 12(2), 131-138. doi: 10. 1007/s10989-005-9010-3.
94. Sadeghi, A. M., Dorkoosh, F. A., Avadi, M. R., Weinhold, M., et al. (2008). Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 70(1), 270-278. doi: 10. 1016/j. ejpb. 2008. 03. 004.
95. Coppi, G., Iannuccelli, V., Leo, E., Bernabei, M. T., Cameroni, R. (2001). Chitosan-alginate microparticles as a protein carrier. Drug Development and Industrial Pharmacy, 27(5), 393-400. doi: 10. 1081/DDC-100104314.
96. Douglas, K. L., & Tabrizian, M. (2005). Effect of experimental parameters on the formation of alginate-chitosan nanoparticles and evaluation of their potential application as DNA carrier. Journal of Biomaterials Science, 16(1), 43-56. doi: 10. 1163/1568562052843339.
97. Sarmento, B., Ferreira, D., Veiga, F., Ribeiro, A. (2006). Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydrate Polymers, 66, 1-7. doi: 10. 1016/j. carbpol. 2006. 02. 008.
98. Zhang, Y., Yang, W., Wang, C., Hu, J., Fu, S., Dong, L., Wu, L., Shen, X. (2007). Nanoparticles based on the complex of chitosan and polyaspartic acid sodium salt: preparation, characterization and the use for 5-fluorouracil delivery. European Journal of Pharmaceutics and Biopharmaceutics, 67, 621-631. doi: 10. 1016/j. ejpb. 2007. 04. 007.
99. Zhang, D. Y., Shen, X. Z., Wang, J. Y., Dong, L., Zheng, Y. L., Wu, L. L. (2008). Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice. World Journal of Gastroenterology, 14, 3554-3562. doi: 10. 3748/wjg. 14. 3554.
100. Lee, J. E., Khan, S. A., Lim, K. H. Chitosan-nanoparticle preparationby polyelectrolyte complexation. 1-2. Available online: http://wjoe. hebeu. edu. cn/ICCE-17%20proceedings%20Hawaii%20USA/Lee,%20Eun-Ju%20%28Kyungpook%20Nat. U.,%20Daegu,%20Korea%29%20%20541. pdf. Accessed: 23 Jun 2012.
101. Mourao, P. A. S., & Pereira, M. S. (1999). Searching for alternatives to heparin: sulfated fucans from marine invertebrates. Trends in Cardiovascular Medicine, 9, 225-232. doi: 10. 1016/S1050-1738(00)00032-3.
102. Mi, F. L., Shyu, S. S., Kuan, C. Y., Lee, S. L., Lu, K. T., Jang, S. F. (1999). Chitosan-polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. II. Effect of pH-dependent ionic crosslinking or interpolymer complex using tripolyphosphate or polyphosphate as reagent. Journal of Applied Polymer Science, 74, 1093-1107. doi: 10. 1002/(SICI)1097-4628(19991114)74: 7< 1868:: AID-APP32> 3. 0. CO; 2-N.
103. Singla, A. K., & Chawla, M. (2001). Chitosan: some pharmaceutical and biological aspects-an update. The Journal of Pharmacy and Pharmacology, 53(8), 1047-1067. doi: 10. 1211/0022357011776441.
104. Tapia, C., Escobar, Z., Costa, E., Sapag-Hagar, J., Valenzuela, F., Basualto, C., Nella, G. M., Yazdano-Pedram, M. (2004). Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazemclorhydrate release systems. European Journal of Pharmaceutics and Biopharmaceutics, 57(1), 65-75. doi: 10. 1016/S0939-6411(03)00153-X.
105. Vila, A., Sanchez, A., Janes, K., Behrens, I., Kissel, T., Vila-Jato, J. L., Alonso, M. J. (2004). Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. European Journal of Pharmaceutics and Biopharmaceutics, 57(1), 123-131. doi: 10. 1016/j. ejpb. 2003. 09. 006.
106. Borchard, G. (2001). Chitosan for gene delivery. Advanced Drug Delivery Reviews, 52(2), 145-150. doi: 10. 1016/S0169-409X(01)00198-3.
107. Thanou, M., Florea, B., Geldof, M., Junginger, H. E., Borchard, G. (2002). Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials, 23(1), 153-159. doi: 10. 1016/S0142-9612(01)00090-4.
108. Nagasaki, T., Hojo, M., Uno, A., Satch, T., Koumoto, K., Mizu, M., Sakurai, K., Shinkai, S. (2004). Long-term expressionwith a cationic polymer derived from a natural polysaccharide: schizophyllan. Bioconjugate Chemistry, 15(2), 249-259. doi: 10. 1021/bc034178x.
109. Mansouri, S., Lavigne, P., Corsi, K., Benderdour, M., Beaumont, E., Fernandes, J. C. (2004). Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficiency. European Journal of Pharmaceutics and Biopharmaceutics, 57(1), 1-8. doi: 10. 1016/S0939-6411(03)00155-3.
110. Sashiwa, H., Thompson, J. M., Das, S. K., Shigenasa, Y., Tripathy, S., Roy, R. (2000). Chemical modification of chitosan: binding proprieties of a-galactosyl-chitosan conjugates. Potential inhibitors in acute rejection following xeno-transplantation. Biomolecules, 1(3), 303-305. doi: 10. 1021/bm005536r.
111. Sharma, A., Mondal, K., Gupta, M. N. (2003). Separation of enzymes by sequential macroaffinity ligand-facilitated three-phase partitioning. Journal of Chromatography A, 995(1& 2), 127-134. doi: 10. 1016/S0021-9673(03)00522-3.
112. Sasaki, C., Kristiansen, A., Fukamizo, T., Varum, K. M. (2003). Biospecific fractionation of chitosan. Biomolecules, 4(6), 1686-1690. doi: 10. 1021/bm034124q.
113. Park, S. I., & Zhao, Y. (2004). Incorporation of a high concentration of mineral or vitamin into chitosan-based films. Journal of Agricultural and Food Chemistry, 52(7), 1933-1939. doi: 10. 1021/jf034612p.
114. Silva, C. L., Pereira, J. C., Ramalho, A., Pais, A. A. C. C., Sousa, J. S. J. (2008). Films based on chitosan polyelectrolyte complexes for skin drug delivery: development and characterisation. Journal of Membrane Science, 320, 268-279. doi: 10. 1016/j. memsci. 2008. 04. 011.
115. Ruel-Gariepy, E., Chenite, A., Chaput, C., Guirguis, S., Lerous, J. (2000). Characterization of thermosensitive chitosan gels for the sustained delivery of drugs. International Journal of Pharmaceutics, 203(1-2), 89-98. doi: 10. 1016/S0378-5173(00)00428-2.
116. Ramanathan, S., & Block, L. H. (2001). The use of chitosan gels as matrices for electrically-modulated drug delivery. Journal of Controlled Release, 70(1-2), 109-123. doi: 10. 1016/S0168-3659(00)00333-3.
117. Vinogradov, S. V., Bronich, T. K., Kabanow, A. V. (2002). Synthesis of nanogel carrier for delivery of active phosphorylated nucleoside analogues. Advanced Drug Delivery Reviews, 54(1), 135-147.
118. Kofuji, K., Akamine, H., Qian, C. J., Watanaba, K., Togan, Y., Nishimura, M., Sugiyana, I., Murata, Y., Kawashima, S. (2004). Therapeutic efficacy of sustained drug release from chitosan gel on local inflammation. International Journal of Pharmaceutics, 272(1-2), 65-78. doi: 10. 1016/j. ijpharm. 2003. 11. 036.
119. Bergera, J., Reista, M., Mayera, J. M., Feltb, O., Gurny, R. (2004). Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics, 57(1), 35-52. doi: 10. 1016/S0939-6411(03)00160-7.
120. El-Shabouri, M. H. (2002). Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. International Journal of Pharmaceutics, 249, 101-108. doi: 10. 1016/S0378-5173(02)00461-1.
121. Niwa, T., Takeuchi, H., Hino, T., Kunou, N., Kawashima, Y. (1994). In vitro drug release behavior of d, l-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. Journal of Pharmaceutical Sciences, 83(5), 727-732. doi: 10. 1002/jps. 2600830527.
122. Lim, S. T., Martin, G. P., Berry, D. J., Brown, M. B. (2000). Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. Journal of Controlled Release, 66(2-3), 281-292. doi: 10. 1016/S0168-3659(99)00285-0.
123. Jaganathan, K. S., Rao, Y. U., Singh, P., Prabakaran, D., Gupta, S., Jain, A., Vyas, S. P. (2005). Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(d, l-lactic-co-glycolic acid) versus chitosan microspheres. International Journal of Pharmaceutics, 294(1-2), 23-32. doi: 10. 1016/j. ijpharm. 2004. 12. 026.
124. Tønnesen, H. H., & Karlsen, J. (2002). Alginate in drug delivery systems. Drug Development and Industrial Pharmacy, 28(6), 621-630. doi: 10. 1081/DDC-120003853.
125. Rajaonarivony, M., Vauthier, C., Couarraze, G., Puisieux, F., Couvreur, P. (1993). Development of a new drug carrier made from alginate. Journal of Pharmaceutical Sciences, 82(8), 912-917. doi: 10. 1002/jps. 2600820909.
126. Pandey, R., Ahmad, Z., Sharma, S., Khuller, G. K. (2005). Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. International Journal of Pharmaceutics, 301(1-2), 268-276. doi: 10. 1016/j. ijpharm. 2005. 05. 027.
127. Hoa, L. T. M., Chi, N. T., Triet, N. M., Nhan, L. N. T., Chien, D. M. (2009). Preparation of drug nanoparticles by emulsion evaporation method. Journal of Physics Conference Series, 187, 1-4. doi: 10. 1088/1742-6596/187/1/012047.
128. Bungenberg de Jong, H. G. (1949). A survey of the study objects in this volume. In H. R. Kruyt (Ed.), Colloid science vol II (pp. 1-18). Amsterdam: Elsevier.
129. Okhamafe, A. O., Amsden, B., Chu, W., Goosen, M. F. A. (1996). Modulation of protein release from chitosan-alginate microcapsules using pH- sensitive polymer hydroxypropyl methylcellulose acetate succinate. Journal of Microencapsulation, 13(5), 497-508. doi: 10. 3109/02652049609026035.
130. Mooren, F. C., & Berthold, A. (1998). Influence of chitosan microspheres on the transport of prednisone sodium phosphate across HT-29 cell monolayers. Pharmaceutical Research, 15(1), 58-65. doi: 10. 1023/A: 1011996619500.
131. Sonvico, F., Cagnani, A., Rossi, A., Motta, S., Di Bari, M. T., Cavatorta, F., Alonso, M. J., Deriu, A., et al. (2006). Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. The International Journal of Pharmaceutics, 324(1), 67-73. doi: 10. 1016/j. ijpharm. 2006. 06. 036.
132. Leong, K. W., Mao, H. Q., Truong-Le, V. L., Roy, K., Walsh, S. M., August, J. T. (1998). DNA-polycation nanospheres as non-viral gene delivery vehicles. Journal of Controlled Release, 53(1-3), 183-193. doi: 10. 1016/S0168-3659(97)00252-6.
133. Roy, K., Mao, H. Q., Huang, S. K., Leong, K. W. (1999). Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Medicine, 5(4), 387-391. doi: 10. 1038/7385.
134. Bhattarai, N., Ramay, H. R., Chou, S. H., Zhang, M. (2006). Chitosan and lactic acid-grafted chitosan nanoparticles as carriers for prolonged drug delivery. International Journal of Nanomedicine, 1(2), 181-187. doi: 10. 2147/nano. 2006. 1. 2. 18.
135. Tien, C. L., Lacroix, I.-S. P., Mateescu, M. A. (2003). N-acylated chitosan: hydrophobic matrices for controlled drug release. Journal of Controlled Release, 93(1), 1-13. doi: 10. 1016/S0168-3659(03)00327-4.
136. Yoo, H. S., Lee, J. E., Chung, H., Kwon, I. C., Jeong, S. Y. (2005). Self -assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. Journal of Controlled Release, 103(1), 235-243. doi: 10. 1016/j. jconrel. 2004. 11. 033.
137. Park, J. H., Kwon, S., Nam, J. O., et al. (2005). Self-assembled nanoparticles based on glycol chitosan bearing 5 β-cholanic acid for RGD peptide delivery. Journal of Controlled Release, 95(3), 579-588. doi: 10. 1016/j. jconrel. 2003. 12. 020.
138. Zhang, J., Chen, X. G., Li, Y. Y., Liu, C. S. (2007). Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomedicine, 3(4), 258-265. doi: 10. 1016/j. nano. 2007. 08. 002.
139. Kim, J. H., Kim, Y. S., Park, K., et al. (2008). Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. Journal of Controlled Release, 127(1), 41-49. doi: 10. 1016/j. jconrel. 2007. 12. 014.
140. Chen, C. C., Tsai, T. H., Huang, Z. R., Fang, J. F. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. European Journal of Pharmaceutics and Biopharmaceutics, 74(3), 474-482. doi: 10. 1016/j. ejpb. 2009. 12. 008.
141. Müller, R. H., Petersen, R. D., Hommoss, A., Pardeike, J. (2007). Nanostructured lipid carriers (NLC) in cosmetic dermal products. Advanced Drug Delivery Reviews, 59(6), 522-530. doi: 10. 1016/j. addr. 2007. 04. 012.
142. Mo, Y., & Lim, L. (2004). Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nano particles by A549 cells. Journal of Pharmaceutical Sciences, 93(1), 20-28. doi: 10. 1002/jps. 10507.
143. Yeh, T. K., Lu, Z., Wientjes, M. G., Au, J. L.-S. (2005). Formulating paclitaxel in nanoparticles alters its disposition. Pharmaceutical Research, 22(6), 867-874. doi: 10. 1007/s11095-005-4581-4.
144. Stevens, P. J., Sekido, M., Lee, R. J. (2004). Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation. Anticancer Research, 24(1), 161-165. doi: 0250-7005/2004$2. 00+. 40.
145. Stevens, P. J., Sekido, M., Lee, R. J. (2004). A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharmaceutical Research, 21(12), 2153-2157. doi: 10. 1007/s11095-004-7667-5.
146. Wu, J., Xiaobin, Z., Lee, R. J. (2007). Lipid-based nanoparticulate drug delivery systems. In D. Thassu, M. Deleers, & Y. Pathak (Eds.), Nanoparticulate drug delivery systems (1st ed.). New York: Informa Healthcare USA, Inc.
147. Puri, A., Loomis, K., Smith, B., et al. (2009). Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Critical Reviews in Therapeutic Drug Carrier Systems, 26(6), 523-580.
148. Wissing, S. A., & Muller, R. H. (2003). The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. European Journal of Pharmaceutics and Biopharmaceutics, 56(1), 67-72. doi: 10. 1016/j. addr. 2003. 12. 002.
149. Wissing, S. A., Kayser, O., Muller, R. H. (2004). Solid lipid nanoparticles for parenteral drug delivery. Advanced Drug Delivery Reviews, 56(9), 1257-1272. doi: 10. 1016/j. addr. 2003. 12. 002.
150. Heurtault, B., Saulnier, P., Pech, B., Proust, J. E., Benoit, J. P. (2002). A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharmaceutical Research, 19(6), 875-880. doi: 10. 1023/A: 1016121319668.
151. Charcosset, C., El-Harati, A., Fessi, H. (2005). Preparation of solid lipid nanoparticles using a membrane contactor. Journal of Controlled Release, 108(1), 112-120. doi: 10. 1016/j. jconrel. 2005. 07. 023.
152. Schwarz, C., Mehnert, W., Lucks, J. S., Muller, R. H. (1994). Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization. Journal of Controlled Release, 30, 83-96. doi: 10. 1016/0168-3659(94)90047-7.
153. Westesen, K., Bunjes, H., Koch, M. H. J. (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. Journal of Controlled Release, 48, 223-236. doi: 10. 1016/S0168-3659(97)00046-1.
154. Uner, M., & Yener, G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. International Journal of Nanomedicine, 2(3), 289-300.
155. Liu, Z., Zhang, X., Wu, H., Li, J., Shu, L., Liu, R., Li, L., Li, N. (2011). Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Development and Industrial Pharmacy, 37(4), 475-481. doi: 10. 3109/03639045. 2010. 522193.
156. Montenegro, L., Campisi, A., Sarpietro, M. G., et al. (2011). In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm, 37(6), 737-746.
157. Seyfoddin, A., Shaw, J., Al-Kassas, R. (2010). Solid lipid nanoparticles for ocular drug delivery. Drug Delivery, 17(7), 467-489. doi: 10. 3109/10717544. 2010. 483257.
158. Serpe, L., Canaparo, R., Daperno, M., Sostegni, R., Martinasso, G., Muntoni, E., Ippolito, L., Vivenza, N., Pera, A., Eandi, M., Gasco, M. R., Zara, G. P. (2010). Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. European Journal of Pharmaceutical Sciences, 39(5), 428-436. doi: 10. 1016/j. ejps. 2010. 01. 013.
159. Zhang, X. G., Miao, J., Dai, Y. Q., Du, Y. Z., Yuan, H., Hu, F. Q. (2008). Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. International Journal of Pharmaceutics, 361(1-2), 239-244. doi: 10. 1016/j. ijpharm. 2008. 06. 002.
160. Teeranachaideekul, V., Muller, R. H., Junyaprasert, V. B. (2007). Encapsulation of ascorbylpalmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. International Journal of Pharmaceutics, 340(1-2), 198-206. doi: 10. 1016/j. ijpharm. 2007. 03. 022.
161. Yuan, H., Wang, L. L., Du, Y. Z., You, J., Hu, F. Q., Zeng, S. (2007). Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids and Surfaces. B, Biointerfaces, 60(2), 174-179. doi: 10. 1016/j. colsurfb. 2007. 06. 011.
162. Jenning, V., Thunemann, A. F., Gohla, S. H. (2000). Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. International Journal of Pharmaceutics, 1999, 167-177. doi: 10. 1016/S0378-5173(00)00378-1.
163. 1H-NMR study. International Journal of Pharmaceutics, 205, 15-21. doi: 10. 1016/S0378-5173(00)00462-2.
164. Joshi, M., & Patravale, M. (2006). Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of Valdecoxib. Drug Development and Industrial Pharmacy, 32(8), 911-918.
165. Geßner, A., Olbrich, C., Schroder, W., Kayser, O., Muller, R. H. (2001). The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. International Journal of Pharmaceutics, 214(1-2), 87-91. doi: 10. 1016/S0378-5173(00)00639-6.
166. Thevenot, J., TroutierAL, D. L., Delair, T., Ladaviere, C. (2007). Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules, 8, 3651-3660. doi: 10. 1021/bm700753q.
167. Zhang, L., Chan, J. M., Gu, F. X., Rhee, J. W., Wang, A. Z., Radovic-Moreno, A. F., et al. (2008). Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano, 2, 1696-1702. doi: 10. 1021/nn800275r.
168. Chan, J. M., Zhang, L. F., Tong, R., Ghosh, D., Gao, W., et al. (2010). Spatio-temporal controlled delivery of nanoparticles to injured vasculature. Proceedings of the National Academy of Sciences, 107(5), 2213-2218. doi: 10. 1073/pnas. 0914585107.
169. Yadav, K. S., & Sawant, K. K. (2010). Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech, 11(3), 1456-1465. doi: 10. 1208/s12249-010-9519-4.
170. Fang, R. H., Aryal, S., Hu, C. M., Zhang, L. (2010). Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir, 26(22), 16958-16962. doi: 10. 1021/la103576a.
171. Ling, G., Zhang, P., Zhang, W., Sun, J., et al. (2010). Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. Journal of Controlled Release, 148(2), 241-248. doi: 10. 1016/j. jconrel. 2010. 08. 010.
172. Wang, A. Z., Gu, F., Zhang, L., Chan, J. M., Radovic-Moreno, A., Shaikh, M. R., Farokhzad, O. C. (2008). Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy, 8(8), 1063-1070. doi: 10. 1517/14712598. 8. 8. 1063.
173. Hu, C. M. J., Kaushal, S., Cao, H. S. T., Aryal, S., Sartor, M., et al. (2010). Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcino embryonic antigen (CEA) presenting pancreatic cancer cells. Molecular Pharmaceutics, 7(3), 914-920. doi: 10. 1021/mp900316a.
174. Li, J., Ying-zi He, Y., Li, W., Shen, Y., Li, Y., Wang, Y. (2010). A novel polymer-lipid hybrid nanoparticle for efficient non-viral gene delivery. Acta Pharmacologica Sinica, 31, 509-514. doi: 10. 1038/aps. 2010. 15.
175. Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., Sasisekharan, R. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436(7050), 568-572. doi: 10. 1038/nature03794.
176. Yiu, T., Li, K., Li, P. J., Liu, B., Feng, S. S. (2010). Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials, 31, 330-338. doi: 10. 1016/j. biomaterials. 2009. 09. 036.
177. Salvador-Morales, C., Zhang, L., Langer, R., Farokhzad, O. C. (2009). Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials, 30, 2231-2240. doi: 10. 1016/j. biomaterials. 2009. 01. 005.
178. Panyam, J., & Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews, 55(3), 329-347. doi: 10. 1016/S0169-409X(02)00228-4.
179. Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., Amidon, G. L. (1997). The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceutical Research, 14(11), 1568-1573. doi: 10. 1023/A: 1012126301290.
180. Desai, M. P., Labhasetwar, V., Amidon, G. L., Levy, R. J. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharmaceutical Research, 13(12), 1838-1845. doi: 10. 1023/A: 1016085108889.
181. Zauner, W., Farrow, N. A., Haines, A. M. (2001). In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. Journal of Controlled Release, 71(1), 39-51. doi: 10. 1016/S0168-3659(00)00358-8.
182. Redhead, H. M., Davis, S. S., Illum, L. (2001). Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. Journal of Controlled Release, 70(3), 353-363. doi: 10. 1023/A: 1022604120952.
183. Dwibhashyam, V. S. N. M., & Nagappa, A. N. (2008). Strategies for enhanced drug delivery to the central nervous system. Indian Journal of Pharmaceutical Sciences, 70(2), 145-153. doi: 10. 4103/0250-474X. 41446.
184. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H., Begley, D. J. (2003). Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical Research, 20(3), 409-416. doi: 10. 1023/A: 1022604120952.
185. Jores, K., Mehnert, W., Mader, K. (2003). Physicochemical investigations on solid-lipid nanoparticles and on oil loaded solid-lipid nanoparticles: a nuclear magnetic resonance and electron spin resonance study. Pharmaceutical Research, 20, 1274-1283. doi: 10. 1023/A: 1025065418309.
186. Maestrell, F., Mura, P., Alonso, M. J. (2004). Formulation and characterization of triclosan sub-micronemulsions and nanocapsules. Journal of Microencapsulation, 21(8), 857-864. doi: 10. 1080/02652040400015411.
187. Lochmann, D., Vogel, V., Weyermann, J., et al. (2004). Physicochemical characterization of protamine-phosphorothioate nanoparticles. Journal of Microencapsulation, 21(6), 625-641. doi: 10. 1080/02652040400000504.
188. Geze, A., Putaux, J. L., Choisnard, L., Jehan, P., Wouessidjewe, D. (2004). Long term shelf stability of amphiphilic B-cyclodextrin nanospheres suspensions monitored by dynamic light scattering and cryo-transmission electron microscopy. Journal of Microencapsulation, 21, 607-613. doi: 10. 1080/02652040400008457%20.
189. Wang, X., Dai, J., Chen, Z., et al. (2004). Bioavailability and pharmacokinetics of cyclosporine A loaded pH-sensitive nanoparticles for oral administration. Journal of Controlled Release, 97, 421-429. doi: 10. 1016/j. jconrel. 2004. 03. 003.
190. Muniyappan, S. V. T., Karatgi, P., Prabu, R., Pillai, R. (2008). Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Development and Industrial Pharmacy, 34(11), 1209-1218. doi: 10. 1080/03639040802005024.
191. Yoo, H. S., & Park, T. G. (2004). Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. Journal of Pharmaceutical Sciences, 93, 488-495. doi: 10. 1002/jps. 10573.
192. Alphandary, H. P., Aboubaker, M., Jaillard, D., Couvreur, P., Vauthier, C. (2003). Visualization of insulin loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharmaceutical Research, 20(7), 1071-1084. doi: 10. 1023/A: 1024470508758.
193. Alexis, F., Pridgen, E., Molnar, L. K., Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), 505-515. doi: 10. 1021/mp800051m.
194. Bershteyn, A., Chaparro, J., Yau, R., Kim, M., Reinherz, E., et al. (2008). Polymer-supported lipid shells, onions, and flowers. Soft Matter, 4(9), 1787-1791. doi: 10. 1039/b804933e.
195. Govender, T., Stolnik, S., Garnett, M. C., Illum, L., Davis, S. S. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. Journal of Controlled Release, 57(2), 171-185. doi: 10. 1016/S0168-3659(98)00116-3.
196. Govender, T., Riley, T., Ehtezazi, T., Garnett, M. C., Stolnik, S., Illum, L., Davis, S. S. (2000). Defining the drug incorporation properties of PLA-PEG nanoparticles. International Journal of Pharmaceutics, 199(1), 95-110. doi: 10. 1016/S0378-5173(00)00375-6.
197. Chen, Y., McCulloch, R. K., Gray, B. N. (1994). Synthesis of albumin-dextran sulfate microspheres possessing favourable loading and release characteristics for the anti-cancer doxorubicin. Journal of Controlled Release, 31(1), 49-54. doi: 10. 1016/0168-3659(94)90250-X.
198. Peracchia, M., Gref, R., Minamitake, Y., Domb, A., Lotan, N., Langer, R. (1997). PEG-coated nanospheres from amphiphillic diblock and multiblock copolymers: investigation of their drug encapsulation and release characteristics. Journal of Controlled Release, 46(3), 223-231. doi: 10. 1016/S0168-3659(96)01597-0.
199. Aryal, S., Hu, C. M. J., Zhang, L. F. (2010). Polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano, 4, 251-258. doi: 10. 1021/nn9014032.
200. Kundu, J., Chung, Y. I., Kim, Y. H., Taeb, G., Kundu, S. C. (2010). Silk fibroin nanoparticles for cellular uptake and control release. International Journal of Pharmaceutics, 388(1-2), 242-250. doi: 10. 1016/j. ijpharm. 2009. 12. 052.
201. Kaul, G., & Amiji, M. (2002). Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharmaceutical Research, 19(7), 1061-1067. doi: 10. 1023/A: 1016486910719.
202. Nam, H. Y., Kwon, S. M., Chung, H., et al. (2009). Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. Journal of Controlled Release, 135(3), 259-267. doi: 10. 1016/j. jconrel. 2009. 01. 018.
203. Jeong, Y. I., Jin, S. G., Kim, I. Y., et al. (2010). Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro. Colloids and Surfaces B, 79(1), 149-155. doi: 10. 1016/j. colsurfb. 2010. 03. 037.
204. Verdun, C., Brasseur, F., Vranckx, H., Couvreur, P., Roland, M. (1990). Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles. Cancer Chemotherapy and Pharmacology, 26(1), 13-18. doi: 10. 1007/BF0294028.
205. Storm, G., Belliot, S., Daemen, T., Lasic, D. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews, 17, 31-48. doi: 10. 1016/0169-409X(95)00039-A.
206. Jeon, S. I., Lee, J. H., Andrade, J. D., De Gennes, P. G. (1991). Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. Journal of Colloid and Interface Science, 142, 149-158. doi: 10. 1016/0021-9797(91)90043-8.
207. Stella, B., Arpicco, S., Peracchia, M., Desmaele, D., Hoebeke, J., Renoir, M., Angelo, J., Cattel, L., Couvreur, P. (2000). Design of folic acid-conjugated nanoparticles for drug targeting. Journal of Pharmaceutical Sciences, 89(11), 1452-1464. doi: 10. 1002/1520-6017(200011)89: 11< 1452:: AID-JPS8> 3. 0. CO; 2-P.
208. Larsen, A. K., Escargueil, A. E., Skladanowski, A. (2000). Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacology and Therapeutics, 85(3), 217-229. doi: 10. 1016/S0163-7258(99)00073-X.
209. Bennis, S., Chapey, C., Couvreur, P., Robert, J. (1994). Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. European Journal of Cancer, 30A(1), 89-93.
210. Damge, C., Michel, C., Aprahamian, M., Couvreur, P., Devissaguet, J. P. (1990). Nanocapsules as carriers for oral peptide delivery. Journal of Controlled Release, 13, 233-239. doi: 10. 1016/0168-3659(90)90013-J.
211. Brandtzaeg, P., Berstad, A., Farstad, I., Haraldsen, G., Helgeland, L., Jahnsen, F., Johansen, F., Natvig, I., Nilsen, E., Rugtveit, J. (1997). Mucosal immunity-a major adaptive defense mechanism. Behring Institute Mitteilungen, 98(1), 1-23.
212. Moghimi, S. M., Hunter, A. C., Murray, J. C. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacological Reviews, 53, 283-318. doi: 0031-6997/01/5302-283-318$3. 00.
213. Bromberg, L. E., Ron, E. S. (1998). Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Advanced Drug Delivery Reviews, 31(3), 197-221. doi: 10. 1016/S0169-409X(97)00121-X.
214. Haltner, E., Easson, J., Lehr, C. (1997). Lectins and bacterial invasion factors for controlling endo- and transcytosis of bioadhesive drug carrier systems. European Journal of Pharmaceutics and Biopharmaceutics, 44, 3-13.
215. Hussain, N., Jani, P. U., Florence, A. T. (1997). Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharmaceutical Research, 14(5), 613-618. doi: 10. 1023/A: 1012153011884.
216. Russell-Jones, G. J., Arthur, L., Walker, H. (1999). Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. International Journal of Pharmaceutics, 179(2), 247-255. doi: 10. 1016/S0378-5173(98)00394-9.
217. Veiseh, O., Sun, C., Fang, C., Bhattarai, N., Gunn, J., Kievit, F., Du, K., Pullar, B., Lee, D., Ellenbogen, R. G., Olson, J., Zhang, M. (2009). Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Research, 69, 6200-6207.
218. Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., Amin, A. F. (2009). Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs, 23(1), 35-58. doi: 10. 2165/0023210-200923010-00003.
219. Lockman, P. R., Koziara, J. M., Mumper, R. J., et al. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. Journal of Drug Targeting, 12(9-10), 635-641. doi: 10. 1080/10611860400015936.
220. Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M. A., Forni, F. (2005). Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. Journal of Controlled Release, 108(1), 84-96. doi: 10. 1016/j. jconrel. 2005. 07. 013.
221. Tahara, K., Miyazaki, Y., Kawashima, Y., Kreuter, J., Yamamoto, H. (2011). Brain targeting with surface-modified poly(d, l-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. European Journal of Pharmaceutics and Biopharmaceutics, 77(1), 84-88. doi: 10. 1016/j. ejpb. 2010. 11. 002.
222. Cho, K., Wang, X., Nie, S., et al. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clinicalo Cancer Research, 14(5), 1310-1316. doi: 10. 1158/1078-0432. CCR-07-1441.